,
10 tweets,
2 min read
Read on Twitter
@TheBMA here raises an important point about medicines regulation in the longer term after Brexit.
The point is here. If the final relationship takes the U.K. outside the EU medicines regime, then it will need a separate system of regulatory approval. 
Regulatory approval for medicines is (rightly) very expensive for applicants. It involves thorough checking of extensive test and trial data so as to ensure that medicines are safe, effective, and if good quality.
Most pharma companies concentrate on getting approval in the 2 big jurisdictions first. 🇺🇸 and EU. Smaller jurisdictions come later. So for example Canada therefore gets new medicines later.
Out of the EU a separate U.K. approvals process means delay.
We could just automatically passport any medicine approved in the EU. But that would destroy our own regulatory capacity (which currently plays a major role in the EU system). And it is hardly taking back control - as voters would point out when something went wrong.
Further problem: pharmacovigilance. That is the complex system that requires pharma companies and healthcare professionals to report problems with medicines in use (eg adverse reactions, becoming less effective).
The EU system effectively collated and shares these data across the EU so problems can be spotted swiftly and acted on.
This system is weakened if the U.K. is no longer part of it, or the flow of data becomes less automatic.
These are serious concerns with out any easy or satisfactory answer.
